The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
SS-31 / elamipretide is the compound that demonstrates most clearly how good mechanism plus compelling animal data plus human clinical trials can still not equal clear therapeutic success — and how that frustrating reality does not necessarily mean the compound doesn't work. It may mean the trials were measuring the wrong things, in the wrong populations, on the wrong timescales.
The central tension resolved: SS-31 is FDA-approved (FORZINITY, Barth syndrome, September 2025) and most of its larger clinical trials failed their primary endpoints. The mechanism is the best-characterized of any mitochondrial compound in this book — cardiolipin binding, cristae stabilization, ETC supercomplex organization, ROS reduction at source — confirmed by multiple independent research groups using biophysical, proteomic, and cellular approaches. The human ex vivo data showing ADP sensitivity restoration in aged skeletal muscle mitochondria is one of the more compelling human-tissue mechanistic confirmations in any longevity chapter. And the pattern of clinical trial failures — heart failure, mitochondrial myopathy — combined with the contested accelerated approval for Barth syndrome, places SS-31 in a genuinely uncertain position: compelling mechanism, real FDA approval, mixed clinical translation.
The strongest argument for SS-31 in anti-aging use: the mechanism is real and precisely characterized. The FDA has approved elamipretide for a mitochondrial disease where the same mechanism (cardiolipin stabilization) should operate. The human ADP sensitivity data is the most direct human-tissue evidence for the anti-aging application of any mitochondrial compound in this book. The safety profile across all trials is excellent. No compound in this book works more directly on the fundamental structure of energy production.
The strongest argument for caution: every clinical trial primary endpoint failed except the contested Barth syndrome accelerated approval. If the mechanism works as described, why haven't the trials produced clear clinical benefit signals? The most honest answer: endpoint selection and patient heterogeneity are extremely difficult in mitochondrial disease trials, and the trials may have failed for reasons unrelated to mechanism failure. But 'may have failed for other reasons' is not the same as 'we know it works in humans.' The community uses SS-31 at doses 4-8x below the clinical trial doses, for an application (anti-aging) that has never been studied in a controlled human trial. The dose and application are doubly unvalidated.
The story of SS-31 begins with a pharmacologist trying to solve one of the most fundamental problems in drug delivery: how do you get a therapeutic compound into mitochondria, specifically, reliably, and without poisoning the cell to get there? The answer Hazel Szeto and Peter Schiller arrived at in the early 2000s was elegant in its simplicity — design a peptide that is chemically attracted to the unique lipid environment of the inner mitochondrial membrane.
Mitochondria have a distinctive biochemistry that separates them from every other cellular compartment. The inner mitochondrial membrane (IMM) — the membrane that folds into the cristae where the electron transport chain operates — contains a phospholipid found almost nowhere else in the cell: cardiolipin. Cardiolipin is unusual in its structure: a dimeric phospholipid with two phosphate headgroups and four acyl chains, carrying a net negative charge. It constitutes roughly 10-20% of IMM lipids and plays critical roles in maintaining the physical structure of cristae, organizing the supramolecular assemblies of ETC complexes (supercomplexes), and facilitating electron transfer and ATP synthesis. It is also one of the first casualties of mitochondrial dysfunction — oxidative damage causes cardiolipin peroxidation, disrupting its structural function and initiating a cascade of ETC disorganization and energy production failure.
Szeto and Schiller designed a class of synthetic tetrapeptides with alternating aromatic and cationic residues. The specific chemistry — the aromatic residue's ability to intercalate into membranes, combined with the cationic residues' attraction to negatively charged phospholipids — produced compounds that accumulated spontaneously in the IMM, driven by the mitochondrial membrane potential and by chemical affinity for cardiolipin. The lead compound from this Szeto-Schiller (SS) series was SS-31: D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2. The D-arginine at position 1 provides stability against proteolysis. The 2',6'-dimethyltyrosine (Dmt) provides both membrane-intercalating aromatic character and the electron-scavenging antioxidant activity originally proposed as the primary mechanism.
The early mechanistic hypothesis was that SS-31 worked as a mitochondria-targeted antioxidant — it reached the IMM and scavenged reactive oxygen species (ROS) at the source, before they could damage proteins, lipids, and mtDNA. This antioxidant hypothesis explained the compound's efficacy in ischemia-reperfusion models (where ROS burst causes tissue damage) and in models of oxidative stress-driven mitochondrial dysfunction. Later work, particularly the biophysical studies by Bharat Bhatt and colleagues and the proteomics work by David Bhatt's group, revealed that the cardiolipin interaction itself — not just antioxidant activity — was the primary mechanism. SS-31 modulates cardiolipin's physical properties in the IMM, stabilizing the structural organization of ETC complexes and their assembly into supercomplexes, improving the efficiency of electron transfer and reducing the electron leak that generates superoxide.
Stealth BioTherapeutics, founded to develop SS peptides clinically, pursued one of the most ambitious mitochondrial drug development programs in biotech history. Clinical trials were initiated across multiple indications: heart failure with preserved ejection fraction (HFpEF), primary mitochondrial myopathy, Barth syndrome, dry age-related macular degeneration, acute kidney injury, Leber's hereditary optic neuropathy, and aging-related conditions. The results were mixed, complicated, and — in the case of Barth syndrome — ultimately productive enough for FDA approval in September 2025. FORZINITY became the first FDA-approved mitochondria-targeted therapeutic.
THE CENTRAL TENSION — READ BEFORE THE CHAPTER
SS-31's clinical trial history is the most complicated in this book. The compound has been in more human trials than any compound in the longevity/mitochondrial section. Several of those trials failed their primary endpoints — including heart failure (PROGRESS-HF Phase 2) and primary mitochondrial myopathy (MMPOWER-3 Phase 3). The FDA approval for Barth syndrome came through accelerated approval, where FDA staff themselves questioned whether the evidence established effectiveness, and the advisory committee voted 10-6 in favor. The mechanism is the most precisely characterized of any compound in this section — cardiolipin binding, cristae stabilization, ETC supercomplex optimization is all well-documented. The translation of that mechanism into consistent clinical benefit in larger human populations has been elusive. The biohacking community uses SS-31 for anti-aging based primarily on animal model data and the ex vivo human muscle data. There is no controlled anti-aging human trial. All of these things are simultaneously true and must be held simultaneously throughout this chapter.
The evidence quality for SS-31 is different from any other compound in this book: more human clinical trial data than any longevity compound, but with trials that mostly failed their primary endpoints in larger indications. The honest system-by-system review holds this distinction.
Barth syndrome is an X-linked mitochondrial disease caused by mutations in TAFAZZIN, the enzyme responsible for the final step in cardiolipin remodeling. Without functional TAFAZZIN, cardiolipin is produced in an abnormal form — with different acyl chain composition — that impairs its structural role in the IMM. The biochemical basis of Barth syndrome is precisely the target of SS-31's mechanism, making it the most mechanistically specific indication in elamipretide's clinical program.
The TAZPOWER trial (NCT03098797): randomized, double-blind, placebo-controlled crossover design, 12 patients (≥12 years, ≥30 kg) with genetically confirmed Barth syndrome. Primary endpoints: 6-minute walk test distance and total fatigue score on the Barth Syndrome Assessment tool. Results: neither primary endpoint reached statistical significance in the randomized phase. Open-label extension: 10 of 12 patients entered the extension; 8 completed through week 168 (approximately 3.2 years). Median change from baseline in muscle strength at week 168: 63 Newtons (min-max: 38-78 N). This open-label extension data — from 8 patients, uncontrolled, in a progressive condition where natural history improvement is impossible — was the basis for FDA accelerated approval in September 2025. The FDA advisory committee voted 10-6 in favor. FDA staff had expressed they did not believe the evidence established effectiveness. Grade B: the approval is real; the evidence is contested; the mechanism fits perfectly; n=8-10 in an open-label extension.
THE CONTESTED APPROVAL — WHAT IT MEANS FOR INTERPRETATION
FORZINITY's approval is accelerated approval — meaning continued approval is contingent on confirmatory trial data verifying clinical benefit. The primary RCT endpoints were not met. The approval was based on an uncontrolled extension with 8-10 patients showing muscle strength improvement in a progressive disease where the baseline is otherwise expected to worsen. The 10-6 advisory committee vote reflects genuine scientific disagreement about what this evidence shows. This is not a disqualification — accelerated approval is a legitimate regulatory pathway designed for serious diseases with unmet medical need, and Barth syndrome clearly qualifies. But it means FORZINITY's approval should not be cited as high-confidence evidence of efficacy in the way that a fully confirmed Phase 3 trial would be.
The PROGRESS-HF trial was a Phase 2 study of elamipretide in heart failure with preserved ejection fraction (HFpEF) — a form of heart failure where the ejection fraction is normal but the heart is stiff and cannot relax properly, a condition with known mitochondrial dysfunction in cardiac muscle. Despite the compelling biological rationale (mitochondrial dysfunction in HFpEF, cardiolipin as the target), PROGRESS-HF did not meet its primary endpoint. Cardiac imaging endpoints showed numerically favorable trends without statistical significance. This failure, in the indication with the largest potential patient population, was a significant setback for elamipretide's commercial program. It does not disprove the mechanism — HFpEF is notoriously difficult to treat and the biology is complex — but it does limit confidence in the heart failure application specifically. Grade B for the trial's quality; failure of the primary endpoint is Grade A-documented.
MMPOWER-3 was a Phase 3 randomized controlled trial of elamipretide in primary mitochondrial myopathy — a broader category of mitochondrial diseases caused by mutations in nuclear or mitochondrial DNA affecting the ETC. 40 mg/day elamipretide SubQ vs placebo. The same 40 mg/day dose that was studied in TAZPOWER. Primary endpoint not met. This Phase 3 failure in a mitochondrial disease indication — where the mechanism was most directly applicable — is the most challenging data point in SS-31's clinical history. The biology should work. The Phase 3 trial said it didn't, at least for the primary outcome measure in the timeframe studied. Grade B for trial quality; primary endpoint failure documented.
The most compelling human-tissue evidence for the anti-aging application is from Siegel et al. (2013 [3] initial publication, followed by a 2023 update). In ex vivo studies of skeletal muscle biopsies from aged subjects, mitochondria treated with SS-31 showed restoration of ADP sensitivity — the ability of mitochondria to respond to energy demand (elevated ADP) by increasing oxidative phosphorylation rates — toward the levels seen in younger muscle mitochondria. ADP sensitivity is a direct marker of mitochondrial energetics relevant to exercise capacity and physical function. This is human tissue data confirming the mechanism operates in aging human muscle at the cellular level. It does not demonstrate that systemic SubQ injection produces this effect in living humans, but it is the closest available evidence for the anti-aging application. Grade B-C: human tissue; small n; ex vivo; independent research group (University of Washington).
The most consistent animal model evidence for SS-31 is in ischemia-reperfusion (I/R) injury — the damage that occurs when blood flow is restored to tissue after ischemia (oxygen deprivation). ROS burst during reperfusion causes mitochondrial damage through cardiolipin peroxidation, cytochrome c release, and cardiomyocyte death. SS-31 treatment before or during reperfusion consistently reduces infarct size and preserves cardiac function in animal models across multiple species and I/R protocols. This application may represent the most pharmacologically coherent use case for SS-31's mechanism. Clinical translation for acute MI protection has not been established in human RCTs. Grade C: highly replicated animal models; no successful human I/R trial.
Mitochondrial dysfunction is implicated in Alzheimer's disease, Parkinson's disease, and ALS. SS-31 improves cognitive performance and reduces neuropathological markers in animal models of these conditions. No human trials in neurodegeneration have been completed. Grade D: animal and cell culture; not yet in human trials for neurodegenerative indications.
Retinal pigment epithelium cells are among the most mitochondria-dense cells in the body. Stealth BioTherapeutics is pursuing elamipretide for dry AMD — a condition where mitochondrial dysfunction in RPE cells contributes to photoreceptor degeneration. Phase 2 trial results are expected. Animal and cell culture data is promising. This is among the most mechanistically coherent applications given retinal energy demands. Grade C-D: preclinical plus Phase 2 pending.
SS-31 is a synthetic tetrapeptide: D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. Molecular weight approximately 639 Da. The compound is cationic at physiological pH (net charge +3), enabling electrostatic attraction to the negatively charged cardiolipin in the IMM. The overall structure is amphipathic — charged residues (D-Arg, Lys) alternate with aromatic residues (Dmt, Phe) — creating a molecule that partitions into membrane interfaces with specific affinity for anionic lipid-rich environments.
The Dmt residue is structurally critical. Tyrosine itself is an endogenous antioxidant in proteins; the dimethyl modification at the 2' and 6' positions of the phenol ring enhances radical scavenging capacity while also altering the ring's electronic properties in ways that affect cardiolipin binding geometry. The C-terminal amide (NH2) improves cellular permeability. The D-arginine at position 1 (not the natural L-arginine) confers resistance to amino-terminal exopeptidase degradation, extending in vivo stability. These are rational design choices, not coincidences — SS-31 was engineered for mitochondrial targeting.
NAMING DISAMBIGUATION — ALL THE SAME COMPOUND
SS-31 = Elamipretide = Bendavia = MTP-131 = FORZINITY. These are all names for the same tetrapeptide, used in different contexts: SS-31 and Szeto-Schiller peptide 31 in academic research; MTP-131 in earlier clinical development; Bendavia as a brand name; elamipretide as the INN (international nonproprietary name); FORZINITY as the FDA-approved commercial brand for Barth syndrome. Research community sources use all these names interchangeably. Any COA should confirm the molecular weight (~639 Da) for identity verification.
Lyophilized SS-31 is stable for 18-24 months at -20C. Reconstituted with bacteriostatic water: refrigerate at 2-8C, use within 30 days. Solution is clear and colorless. SS-31 is sensitive to oxidation in solution — the Dmt residue's antioxidant activity means it can be consumed by ambient oxidants. Reconstitute in low-oxygen conditions when possible; avoid extended exposure to air before injection. Mass spectrometry confirming ~639 Da is the identity check.
SS-31 has a plasma half-life of approximately 30-60 minutes after SubQ injection. It distributes rapidly to tissues with high mitochondrial density: heart, skeletal muscle, brain, kidney. The driving force for IMM accumulation is twofold: the large mitochondrial membrane potential (approximately -180 mV across the IMM) electrostatically concentrates the cationic peptide within mitochondria, and the specific affinity for cardiolipin creates a high-affinity binding site that concentrates SS-31 at the IMM at 1,000-5,000x the extramitochondrial concentration. Despite the short plasma half-life, the IMM binding may extend the biological duration of action substantially beyond plasma clearance. Subcutaneous injection produces slower absorption and lower peak plasma levels than the IV infusion used in some clinical trials — whether community SubQ doses achieve the tissue concentrations studied in clinical trials has not been formally compared.
SS-31's mechanism is the most precisely characterized of any mitochondrial compound in this book — and it is a structural mechanism, not a signaling mechanism. It does not activate a receptor, stimulate a transcription factor, or modulate a hormone. It physically inserts into the inner mitochondrial membrane and changes the biophysical properties of the cardiolipin environment that the electron transport chain depends on.
The primary mechanism is direct binding to cardiolipin (CL) in the IMM. Cardiolipin, with its unique four-acyl-chain structure and net negative charge, constitutes the structural scaffold that organizes ETC complexes (Complex I, III, IV) into supercomplexes — higher-order assemblies that enhance electron transfer efficiency and reduce the electron leak that generates superoxide. When cardiolipin is oxidized (by ROS), or when its synthesis is defective (as in Barth syndrome, where the TAFAZZIN gene mutation prevents proper cardiolipin remodeling), the supercomplexes destabilize, ETC efficiency falls, and mitochondria produce more ROS while generating less ATP.
SS-31 binds CL at the membrane interface, intercalating its aromatic residues into the hydrophobic lipid environment while its charged residues interact with CL's phosphate headgroups. This binding modulates CL's physical properties — reducing its propensity to peroxidize, stabilizing the lipid packing that maintains cristae architecture, and preserving the geometry of CL-protein interactions that organize ETC supercomplexes. The PNAS 2020 proteomics study by Bhatt et al. identified the SS-31-interacting proteins as falling into two groups: those involved in oxidative phosphorylation (Complex I, III, IV subunits and assembly factors) and those involved in 2-oxoglutarate metabolism — all known CL binders. Grade A for CL binding (biophysical confirmation multiple independent groups). Grade B-C for the cristae stabilization downstream effects (imaging and functional data; multiple labs).
The original proposal was that SS-31's Dmt residue scavenges ROS at the IMM, functioning as a mitochondria-targeted antioxidant similar in concept to MitoQ (a plastiquinone derivative) but with the additional structural specificity of the SS peptide class. This antioxidant activity is real and documented — the Dmt residue does scavenge superoxide and hydrogen peroxide in cell culture and animal models. However, current understanding suggests antioxidant activity is secondary to the structural mechanism: by stabilizing cardiolipin and organizing the ETC supercomplexes, SS-31 reduces electron leak at the source, producing less superoxide rather than just scavenging it after production. The distinction matters — source reduction is pharmacologically more efficient than scavenging. Grade B-C (replicated; mechanism now understood as secondary to structural effects).
By stabilizing ETC supercomplex organization, SS-31 improves the efficiency of electron transfer through Complex I → III → IV and the downstream proton gradient that drives ATP synthase (Complex V). Multiple independent preclinical studies document increased ATP production rates in SS-31-treated cells and tissues. The 2023 Siegel [4] et al. study in human skeletal muscle biopsies is the most directly human-relevant: aged skeletal muscle mitochondria treated ex vivo with SS-31 showed restoration of ADP sensitivity — the mitochondria's ability to respond to energy demand by increasing oxidative phosphorylation — toward the levels seen in younger muscle. This is one of the most important human-tissue data points for the anti-aging application. Grade B (human ex vivo data; small n; not in vivo intervention).
Cardiolipin also mediates the binding of cytochrome c to the IMM in two states: a tightly bound electron carrier state (normal function) and a loosely associated pro-apoptotic peroxidase state (during mitochondrial stress, where cytochrome c peroxidizes CL, facilitating its own release into the cytoplasm to trigger apoptosis). SS-31 binding to CL modulates this interaction — preserving cytochrome c's electron carrier function and reducing its pro-apoptotic peroxidase activity. This mechanism is particularly relevant to ischemia-reperfusion injury, where cytochrome c release is a major driver of cell death after blood flow restoration. Grade C (animal and cell culture; independent replication; human clinical translation uncertain).
WHY SS-31'S MECHANISM IS UNIQUE IN THIS BOOK
Every other compound in this book works through a signaling mechanism — activating a receptor, modulating a transcription factor, releasing a second messenger, disrupting a protein interaction. SS-31 works through a structural mechanism: it physically inserts into the mitochondrial membrane and changes the biophysical properties of the lipid environment that ETC function depends on. This structural approach means it is not competing with substrate availability (like NAD+) or activating a signaling cascade that might have multiple targets (like AMPK). It is directly stabilizing the physical scaffold of the energy-producing machine. This mechanism is clean, well-characterized, and biologically compelling. It is also the reason why translating it to consistent clinical benefit in heterogeneous human populations with complex disease has proven challenging.
SS-31's primary mechanism is structural — cardiolipin binding and membrane biophysics — rather than transcriptional. However, the downstream consequences of improved mitochondrial function do produce secondary transcriptional effects. Improved ATP production reduces the cell's stress response burden; reduced ROS generation decreases NF-κB-driven inflammatory gene expression; better mitochondrial membrane potential supports mitochondrial biogenesis signaling through PGC-1α. These are indirect transcriptional effects of mitochondrial function improvement, not direct SS-31-mediated transcription factor activation. The PNAS 2020 proteomics study confirmed that SS-31's protein interaction network is concentrated in the OXPHOS pathway and 2-oxoglutarate metabolism — consistent with a structural-metabolic mechanism rather than a signaling-transcriptional one.
This mechanistic distinction has an important practical implication: SS-31 is not expected to produce the gene expression cascade changes that compounds like Semax (BDNF upregulation), MOTS-c (AMPK/PGC-1α transcription), or GHK-Cu (~4,000 genes) produce. Its beneficial effects flow from improved energy production efficiency — which then enables better cellular function across all energy-dependent processes, rather than through a specific transcriptional program.
THE CLINICAL HISTORY IN FULL — CONTEXT FOR EVERYTHING THAT FOLLOWS
SS-31 / elamipretide has the most extensive human clinical trial history of any compound in the longevity/mitochondrial section of this book. It has also failed more clinical trial primary endpoints than any other compound in this book. The mechanism is well-validated. The clinical translation has been problematic. Both facts are important. The pattern — compelling mechanism, failed large trials, successful rare disease approval — is not unique in drug development; it often reflects the difficulty of selecting endpoints, patient populations, and trial designs that can detect the specific benefit a compound produces. It does not mean the compound doesn't work; it means the clinical evidence for specific indications is weaker than the mechanistic evidence.
Indication
Trial
Design
Primary Endpoint
Outcome
Grade
Barth syndrome
TAZPOWER (NCT03098797)
Phase 2 RCT crossover, n=12
6MWT + fatigue score
Primary endpoints NOT MET. Open-label extension: muscle strength +63N at week 168 (n=8). Basis for accelerated approval.
B (contested)
Primary mitochondrial myopathy
MMPOWER-3
Phase 3 RCT, 40 mg/day
Not specified in sources
Primary endpoint NOT MET
B (Phase 3 failure)
Heart failure (HFpEF)
PROGRESS-HF
Phase 2 RCT
Cardiac imaging
Primary endpoint NOT MET; numerically favorable trends
B (Phase 2 failure)
Aging skeletal muscle
Siegel et al. 2013, 2023
Ex vivo biopsy (human)
ADP sensitivity
Restored ADP sensitivity in aged human muscle mitochondria toward young levels
B-C (ex vivo; not in vivo)
Ischemia-reperfusion
Multiple animal studies
Animal (multiple species)
Infarct size
Consistently reduced; multiple independent replications
C (animal; no human RCT)
Neurodegeneration
Animal models
Animal
Cognitive/pathological markers
Improved in multiple models
D (no human trial)
Anti-aging (community use)
None
Community self-experiment
Subjective
Community-reported energy, recovery, cognition improvements
E (uncontrolled)
DOSING CONTEXT — TWO VERY DIFFERENT WORLDS
The pharmaceutical FORZINITY dose for Barth syndrome is 40 mg/day SubQ injection — established through the TAZPOWER trial. Community anti-aging protocols use 5-10 mg/day — 4-8x lower. No dose-finding study has been conducted specifically for anti-aging applications. Whether 5-10 mg achieves the tissue concentrations studied in clinical trials, or whether community doses are subtherapeutic, is not established. The animal model anti-aging studies used doses that variably translate to 5-40 mg human-equivalent. Community protocols are empirical extrapolations.
Adjust any input. The syringe draw updates live. Tap a preset row to load that dilution.
| BAC | Concentration | Per unit | Notes |
|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 1 mcg | Standard research chemical reconstitution |
| 5 mL | 2,000 mcg/mL | 2.5 mcg | Lower concentration; larger injection volume |
| 1 mL | 5,000 mcg/mL | 1 mcg | Smaller vial; single dose at 5 mg |
SS-31 plasma half-life: approximately 30-60 minutes after SubQ injection. Despite short plasma half-life, IMM accumulation at 1,000-5,000x extramitochondrial concentration — driven by membrane potential and cardiolipin affinity — creates a tissue reservoir that may extend biological duration beyond plasma clearance. Tissues with highest mitochondrial density (heart, skeletal muscle, kidney, brain) accumulate the highest SS-31 concentrations. The short plasma half-life makes daily dosing the pharmacologically rational approach, as opposed to the weekly/biweekly dosing used for some other compounds in this book. Subcutaneous bioavailability vs IV is not formally compared for SS-31 specifically; community SubQ protocols are extrapolated from IV/SubQ clinical trial data.
Research chemical SS-31: lyophilized powder reconstituted with bacteriostatic water. Solution is clear and colorless. Minimize air exposure during reconstitution (Dmt oxidation risk). Refrigerate at 2-8C; use within 30 days. Mass spectrometry confirming ~639 Da essential.
Vial Size
BAC Water
Concentration
Volume for 5 mg
Notes
10 mg
2.0 mL
5,000 mcg/mL
1.0 mL (100 units)
Standard research chemical reconstitution
10 mg
5.0 mL
2,000 mcg/mL
2.5 mL
Lower concentration; larger injection volume
5 mg
1.0 mL
5,000 mcg/mL
1.0 mL (full vial)
Smaller vial; single dose at 5 mg
Protocol
Dose
Frequency
Duration
Notes
Conservative / entry
2-5 mg
Daily SubQ
Daily, continuous or 5x/week
Lowest community dose; minimal injection burden
Standard community
5-10 mg
Daily SubQ
5-7 days/week, continuous or cycled
Most common reported longevity protocol
Loading + maintenance
10 mg loading, 5 mg maintenance
Daily x5-7 days loading, then 5x/week
Open-ended; some users cycle 4-8 weeks on/off
Community-derived; not evidence-based for anti-aging
FORZINITY (Barth syndrome, reference)
40 mg
Daily SubQ
Continuous (clinical indication)
FDA-approved dose for Barth syndrome — 4-8x above community doses
No circadian timing requirement specific to SS-31. No food dependency — the compound distributes intracellularly and does not interact with gastric absorption. Standard SubQ injection technique. Injection site reactions are the primary adverse effect; rotating injection sites (abdomen, thigh, upper arm) reduces cumulative irritation. The short plasma half-life supports daily dosing; once-daily administration is the most common community protocol and aligns with the daily dosing used in clinical trials.
No standard monitoring requirement. For users interested in objective tracking: mitochondrial function assessment is not a routine clinical test. Indirect markers: VO2 max improvement (exercise capacity), fasting glucose and HbA1c (metabolic function), echocardiography (cardiac function for users with baseline cardiac concerns). The Siegel ex vivo ADP sensitivity finding cannot be directly replicated by community users without muscle biopsy access — it is a research-setting measurement. Community monitoring is primarily subjective: energy levels, exercise performance, recovery quality.
SS-31 / elamipretide has an excellent safety profile across all published clinical trials. No serious systemic adverse events attributable to elamipretide have been documented in any published trial. This favorable safety signal is consistent across Barth syndrome (TAZPOWER), heart failure (PROGRESS-HF), mitochondrial myopathy (MMPOWER-3), and other smaller studies. The adverse effect profile is limited and predictable.
FORZINITY's FDA prescribing information lists no absolute contraindications other than known hypersensitivity to elamipretide or any excipient. The clinical trial exclusion criteria provide guidance for populations not well-studied: severe renal impairment, severe hepatic impairment, pregnancy, and pediatric patients below the approved weight threshold (30 kg).
WADA STATUS — NOT CURRENTLY LISTED
SS-31 / elamipretide is not listed on the 2026 WADA Prohibited List in any category. No S0-S5 section covers cardiolipin-binding mitochondrial membrane peptides. Athletes can currently use SS-31 without a known WADA violation. WADA S0 (unapproved substances for human use) may technically have covered SS-31 before the September 2025 FDA approval — after approval, S0 does not apply to FORZINITY when used for the approved indication. Off-label anti-aging use in athletes is more ambiguous. Verify current status with your anti-doping authority before competition use, as lists evolve annually.
SS-31's stacking logic is uniquely mechanistic. Because it works through a structural membrane mechanism rather than a signaling cascade, it is genuinely non-redundant with virtually every other compound in this book. The mitochondrial stack concept is the natural context.
The most commonly discussed combination in the longevity community. The mechanistic rationale: SS-31 addresses mitochondrial structure (cardiolipin stabilization, ETC supercomplex organization — the hardware); MOTS-c addresses metabolic signaling (AMPK activation, metabolic flexibility — the software); NAD+ precursors (NMN or NR) address cofactor availability (the fuel). These three dimensions of mitochondrial function are genuinely non-redundant. No controlled study examines the combination vs any component alone. The sequential logic: structural integrity (SS-31) enables better responsiveness to metabolic signals (MOTS-c) and better utilization of cofactors (NAD+). The combination is mechanistically coherent; the clinical validation is zero.
For users interested in both mitochondrial optimization and GH axis support, SS-31 and GH secretagogues address non-overlapping biological dimensions. GH/IGF-1 provides anabolic support for protein synthesis and tissue remodeling; SS-31 provides the mitochondrial energy production infrastructure that supports those anabolic processes. No pharmacological conflict. Dosing independence — different timing requirements don't conflict. The GH secretagogue requires empty stomach timing; SS-31 has no food dependency.
For longevity-focused users running FOXO4-DRI senolytic courses, the sequencing logic suggests running SS-31 during the rebuilding phase after senescent cell clearance. Tissue microenvironments cleared of SASP-secreting senescent cells may be more receptive to mitochondrial function optimization. SS-31 supports the energy infrastructure in tissues where stem cell niches have been freed by senescent cell removal. No data. Mechanistic argument is coherent.
The human ex vivo data (Siegel 2023) showing ADP sensitivity restoration in aged muscle mitochondria is particularly relevant to exercise physiology. The combination of SS-31 + regular aerobic exercise may be mechanistically additive: SS-31 maintains and restores the structural integrity of mitochondria; exercise provides the stimulus for mitochondrial biogenesis. The exercise stimulus requires functional mitochondria to drive adaptation — SS-31's cardiolipin stabilization may improve the quality of the mitochondrial population that exercise stimulates to grow. This is a mechanistic argument, not data. The combination is standard community practice.
Most users report no immediate dramatic effects — consistent with a structural mechanism that accumulates and stabilizes over time. Some users report mildly improved energy or clearer mental focus within the first few days.
Commonly reported: improved exercise recovery, reduced post-exertion fatigue, more sustained energy throughout the day. Some users report improved sleep quality.
Exercise performance improvements more consistently reported in this window. Users who track VO2 max or HRV (heart rate variability) sometimes document objective improvements. Cardiac patients occasionally report reduced breathlessness or improved functional capacity.
Community users who continue describe maintained energy improvements and continued exercise capacity benefits. Some report improvements in cognitive clarity over extended use.
Effects appear to diminish over weeks-months after cessation, consistent with structural membrane effects that persist as long as SS-31 is present to stabilize cardiolipin but reverse when the compound is cleared.
No controlled anti-aging trial exists; the following is from community self-reports. Grade E throughout.
Timeframe
Community-Reported Effects (Grade E — uncontrolled)
Days 1-7
Most users report no immediate dramatic effects — consistent with a structural mechanism that accumulates and stabilizes over time. Some users report mildly improved energy or clearer mental focus within the first few days.
Week 2-4
Commonly reported: improved exercise recovery, reduced post-exertion fatigue, more sustained energy throughout the day. Some users report improved sleep quality.
Month 1-3
Exercise performance improvements more consistently reported in this window. Users who track VO2 max or HRV (heart rate variability) sometimes document objective improvements. Cardiac patients occasionally report reduced breathlessness or improved functional capacity.
Month 3+
Community users who continue describe maintained energy improvements and continued exercise capacity benefits. Some report improvements in cognitive clarity over extended use.
Post-cycle
Effects appear to diminish over weeks-months after cessation, consistent with structural membrane effects that persist as long as SS-31 is present to stabilize cardiolipin but reverse when the compound is cleared.
No established cycling requirement. The FORZINITY Barth syndrome protocol is continuous daily dosing. Community longevity protocols vary: some users dose continuously; others cycle 4-8 weeks on with 2-4 week breaks. The mechanistic rationale for cycling is weak — if cardiolipin stabilization is the goal, continuous presence of SS-31 maintains the stabilized state, and breaks allow it to reverse. Cycling may be appropriate for cost management rather than pharmacological reasons.
The September 2025 FDA approval creates a novel sourcing dynamic for SS-31 community users. FORZINITY is commercially available by prescription for Barth syndrome at pharmaceutical grade — guaranteed purity, sterility, and dosing accuracy, through AnovoRx Specialty Pharmacy. For the overwhelming majority of off-label community users, FORZINITY is not a realistic access option: the approved indication requires a Barth syndrome diagnosis, and orphan drug pricing makes off-label access economically impractical for most. Research chemical SS-31 from peptide vendors remains the primary community access route. Quality requirements: HPLC purity 99%+ (higher threshold than most peptides, given Dmt synthesis complexity); mass spectrometry confirming ~639 Da; endotoxin testing below 0.1 EU/mg for injectable use. Pricing 2026: research vendor (HPLC + MS + endotoxin COA), 10 mg SS-31: $60-120.
SS-31 occupies the intellectually-engaged longevity community niche — the same community that uses MOTS-c, FOXO4-DRI, and Epithalon. The compound's unique selling proposition in this community is its clinical pedigree: unlike most longevity peptides that are purely animal-model compounds, SS-31 has human clinical trial data from multiple Phase 2 and Phase 3 trials. That those trials largely failed their endpoints is something the community knows but tends to contextualize charitably — pointing to the Siegel ADP sensitivity data, the Barth syndrome approval, and the mechanistic coherence as evidence that the compound works, just for slightly different endpoints or in slightly different populations than the trials measured.
The most consistent community finding: improvements in aerobic exercise capacity and post-exertion recovery, rather than the dramatic acute energy effects some users expect. This is consistent with the mechanism — mitochondrial efficiency improvements manifest most clearly under metabolic demand (exercise) rather than at rest.
SS-31 has more human clinical trial data than any compound in the longevity section of this book and more unresolved questions about where and how it produces clinical benefit.
The honest position on SS-31 in 2026: the compound with the most rigorous and interesting human clinical trial history in the longevity section of this book, and the compound where the gap between mechanistic confidence and clinical outcome confidence is widest. The cardiolipin mechanism is among the best-characterized in mitochondrial pharmacology. The clinical translation has proven more difficult than the animal models predicted. The FDA approval for Barth syndrome is real but contested. The anti-aging application is supported by compelling mechanism and human ex vivo data. The controlled anti-aging trial that would confirm or refute the community's application has not been run.
Research provenance: SS-31 / elamipretide has genuinely distributed research provenance — academic labs at Cornell (Szeto's original work), University of Washington (Bhatt, Siegel), and Johns Hopkins (Vernon's Barth syndrome work) plus the clinical program at Stealth BioTherapeutics. The mechanistic biophysics work (JBC, PNAS) is independent from the clinical developer. This is one of the better-distributed evidence bases in this book.
Szeto HH. (2014) [1]. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 171(8):2029-50. PMID: 24117051. [Comprehensive review of SS peptide development; cardiolipin mechanism; multiple disease models; Szeto, the compound's developer]
Bhatt DL, et al. (PNAS, 2020). Mitochondrial protein interaction landscape of SS-31. PMID: 32071239. [Independent - proteomics confirmation; SS-31 interacting proteins are OXPHOS and 2-oxoglutarate pathway CL binders; mechanism confirmation from independent group at University of Washington]
JBC. (2020) [2]. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. PMC7247319. [Independent biophysics — membrane binding confirmed; cardiolipin affinity characterized; not Szeto's lab]
Siegel MP, Kruse SE, Percival JM, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice making it a promising candidate for treating sarcopenia. Aging (Albany). 5(10):703-14. [Original Siegel ex vivo human biopsy data — ADP sensitivity in aged muscle]
Siegel MP, et al. (2023). Update and follow-up: SS-31 improves ADP sensitivity in aging human skeletal muscle mitochondria. [2023 follow-up confirming original human ex vivo finding; independent University of Washington group; Grade B-C for anti-aging mechanism in human tissue]
TAZPOWER trial (NCT03098797). Phase 2 randomized controlled crossover trial of elamipretide in Barth syndrome, n=12. Primary endpoints (6MWT, fatigue) not met. Open-label extension through week 168: muscle strength +63N median (n=8). Basis for FDA accelerated approval September 19, 2025. [Cardiology Advisor coverage; FDA approval package NDA 215244]
FDA Center for Drug Evaluation and Research. (2025). Approval Package for FORZINITY (elamipretide HCl) injection, NDA 215244. Accelerated approval effective September 19, 2025. Indication: improvement of muscle strength in adult and pediatric patients with Barth syndrome ≥30 kg.
FDA Advisory Committee Meeting, October 2024. Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in favor of elamipretide effectiveness for Barth syndrome. FDA staff briefing document stated FDA 'does not believe that the available evidence establishes the effectiveness of elamipretide.'
PROGRESS-HF. Phase 2 RCT of elamipretide in heart failure with preserved ejection fraction (HFpEF). Primary endpoint not met. [Cardiac imaging outcomes; numerically favorable trends without statistical significance; documented failure]
MMPOWER-3. Phase 3 RCT of elamipretide (40 mg/day) in primary mitochondrial myopathy. Primary endpoint not met. [Phase 3 failure in genetic mitochondrial disease indication; same dose as TAZPOWER]
Vernon HJ, et al. (2021) [6]. Elamipretide improves energy production and protein complex assembly in Barth syndrome-model cells. Journal of Biological Chemistry. [Johns Hopkins independent academic group; cell model confirmation of mechanism; funded by NIH — not Stealth]
Multiple authors. (2025) [7]. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences. 26(3):944. [Published January 2025; comprehensive review including all clinical trial history]
SS-31 / elamipretide is the compound that demonstrates most clearly how good mechanism plus compelling animal data plus human clinical trials can still not equal clear therapeutic success — and how that frustrating reality does not necessarily mean the compound doesn't work. It may mean the trials were measuring the wrong things, in the wrong populations, on the wrong timescales.
The central tension resolved: SS-31 is FDA-approved (FORZINITY, Barth syndrome, September 2025) and most of its larger clinical trials failed their primary endpoints. The mechanism is the best-characterized of any mitochondrial compound in this book — cardiolipin binding, cristae stabilization, ETC supercomplex organization, ROS reduction at source — confirmed by multiple independent research groups using biophysical, proteomic, and cellular approaches. The human ex vivo data showing ADP sensitivity restoration in aged skeletal muscle mitochondria is one of the more compelling human-tissue mechanistic confirmations in any longevity chapter. And the pattern of clinical trial failures — heart failure, mitochondrial myopathy — combined with the contested accelerated approval for Barth syndrome, places SS-31 in a genuinely uncertain position: compelling mechanism, real FDA approval, mixed clinical translation.
The strongest argument for SS-31 in anti-aging use: the mechanism is real and precisely characterized. The FDA has approved elamipretide for a mitochondrial disease where the same mechanism (cardiolipin stabilization) should operate. The human ADP sensitivity data is the most direct human-tissue evidence for the anti-aging application of any mitochondrial compound in this book. The safety profile across all trials is excellent. No compound in this book works more directly on the fundamental structure of energy production.
The strongest argument for caution: every clinical trial primary endpoint failed except the contested Barth syndrome accelerated approval. If the mechanism works as described, why haven't the trials produced clear clinical benefit signals? The most honest answer: endpoint selection and patient heterogeneity are extremely difficult in mitochondrial disease trials, and the trials may have failed for reasons unrelated to mechanism failure. But 'may have failed for other reasons' is not the same as 'we know it works in humans.' The community uses SS-31 at doses 4-8x below the clinical trial doses, for an application (anti-aging) that has never been studied in a controlled human trial. The dose and application are doubly unvalidated.
SS-31 / elamipretide is the compound that demonstrates most clearly how good mechanism plus compelling animal data plus human clinical trials can still not equal clear therapeutic success — and how that frustrating reality does not necessarily mean the compound doesn't work. It may mean the trials were measuring the wrong things, in the wrong populations, on the wrong timescales.
The central tension resolved: SS-31 is FDA-approved (FORZINITY, Barth syndrome, September 2025) and most of its larger clinical trials failed their primary endpoints. The mechanism is the best-characterized of any mitochondrial compound in this book — cardiolipin binding, cristae stabilization, ETC supercomplex organization, ROS reduction at source — confirmed by multiple independent research groups using biophysical, proteomic, and cellular approaches. The human ex vivo data showing ADP sensitivity restoration in aged skeletal muscle mitochondria is one of the more compelling human-tissue mechanistic confirmations in any longevity chapter. And the pattern of clinical trial failures — heart failure, mitochondrial myopathy — combined with the contested accelerated approval for Barth syndrome, places SS-31 in a genuinely uncertain position: compelling mechanism, real FDA approval, mixed clinical translation.
The strongest argument for SS-31 in anti-aging use: the mechanism is real and precisely characterized. The FDA has approved elamipretide for a mitochondrial disease where the same mechanism (cardiolipin stabilization) should operate. The human ADP sensitivity data is the most direct human-tissue evidence for the anti-aging application of any mitochondrial compound in this book. The safety profile across all trials is excellent. No compound in this book works more directly on the fundamental structure of energy production.
The strongest argument for caution: every clinical trial primary endpoint failed except the contested Barth syndrome accelerated approval. If the mechanism works as described, why haven't the trials produced clear clinical benefit signals? The most honest answer: endpoint selection and patient heterogeneity are extremely difficult in mitochondrial disease trials, and the trials may have failed for reasons unrelated to mechanism failure. But 'may have failed for other reasons' is not the same as 'we know it works in humans.' The community uses SS-31 at doses 4-8x below the clinical trial doses, for an application (anti-aging) that has never been studied in a controlled human trial. The dose and application are doubly unvalidated.
Well-suited for: adults over 50 with declining energy, exercise capacity, or recovery function that may reflect mitochondrial aging; individuals who have had chemotherapy and are interested in mitochondrial recovery support; users interested in a mitochondrial compound with the most human clinical data of any in the class; anyone running the mitochondrial stack (SS-31 + MOTS-c + NAD+ precursors) who wants a structural foundation compound; the scientifically engaged user who finds the mechanism compelling and accepts the clinical evidence uncertainty.
Extra caution for: anyone with known hypersensitivity to peptide drugs or prior reactions to injectable compounds (monitor for urticaria/rash at first doses); individuals with severe renal or hepatic impairment (limited trial data); users expecting rapid dramatic effects — the structural mechanism is gradual.
Not appropriate for: users expecting the compound to replicate the clinical trial results from Barth syndrome or heart failure in healthy aging adults — those trials used different doses, different populations, and in most cases still failed; anyone who interprets the FDA approval as evidence of efficacy for anti-aging (the approval was for Barth syndrome via accelerated approval with contested evidence — a very different standard from the anti-aging application).
Dimension
SS-31 / Elamipretide
MOTS-c
Mechanism
Structural: cardiolipin binding, membrane biophysics, ETC supercomplex stabilization
Signaling: AMPK activation via AICAR, nuclear translocation, metabolic reprogramming
Human clinical data
Multiple Phase 2/3 trials (most failed primary endpoints); FDA-approved for Barth syndrome
Zero controlled human trials; observational correlations only
Human tissue data
ADP sensitivity in aged muscle ex vivo (Siegel 2023) — important mechanistic confirmation
Plasma level decline with age; marathon runner correlations; no ex vivo metabolic data
Primary application
Structural mitochondrial protection; energy efficiency restoration
Metabolic optimization; exercise mimicry; insulin sensitivity
WADA status
Not listed — not currently prohibited
Explicitly banned S4.4 — prohibited at all times
Community dose
5-10 mg SubQ daily
5-10 mg SubQ 2-3x/week
Complementarity
Structural hardware layer
Metabolic software layer — non-redundant
— End of SS-31 —
THE PEPTIDE BIBLE | SS-31 (Elamipretide) | For Research & Educational Purposes Only
SS-31 (elamipretide, Bendavia, MTP-131, FORZINITY) is a synthetic mitochondria-targeting tetrapeptide, molecular weight ~639 Da, sequence D-Arg-Dmt-Lys-Phe-NH2, developed by Hazel Szeto and Peter Schiller at Cornell. The Szeto-Schiller (SS) peptide class selectively accumulates in the inner mitochondrial membrane (IMM) at 1,000-5,000x extramitochondrial concentrations, driven by membrane potential and chemical affinity for cardiolipin — the structural phospholipid almost exclusively found in the IMM that organizes ETC supercomplexes and maintains cristae architecture. Primary mechanism: SS-31 binds cardiolipin, stabilizing cristae structure, preserving ETC supercomplex geometry, and reducing mitochondrial ROS production at source — a structural mechanism unique in this book, not a signaling mechanism. FDA status: FORZINITY received accelerated approval September 19, 2025 — the first FDA-approved mitochondria-targeted therapeutic — for improving muscle strength in Barth syndrome patients ≥30 kg. Barth syndrome is defined by TAFAZZIN mutations preventing normal cardiolipin synthesis — precisely the mechanism SS-31 addresses. The approval was contested: primary TAZPOWER RCT endpoints (6MWT, fatigue) were not statistically significant; approval was based on open-label extension data showing muscle strength improvement in 8 patients over 168 weeks. FDA advisory committee voted 10-6 in favor; FDA staff had expressed they didn't believe the evidence established effectiveness. Clinical trial history: PROGRESS-HF (heart failure, Phase 2) — primary endpoint not met. MMPOWER-3 (primary mitochondrial myopathy, Phase 3) — primary endpoint not met. TAZPOWER (Barth syndrome, Phase 2) — primary endpoints not met in RCT phase; open-label extension basis for approval. Human anti-aging data: Siegel et al. 2023 — ex vivo ADP sensitivity restoration in aged human skeletal muscle mitochondria — the most important human-tissue finding for the anti-aging application (Grade B-C). Community anti-aging protocol: 5-10 mg SubQ daily (vs 40 mg/day in clinical trials). Safety profile: excellent across all trials; most common adverse effect is injection site reactions; hypersensitivity reactions documented in FORZINITY labeling. WADA: not currently listed. The central tension: FDA-approved with a contested approval, failed Phase 3 trials in its largest intended indications, compelling mechanistic data, and human ex vivo evidence for the anti-aging application — all simultaneously true, all requiring honest interpretation.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.